Article

Global rise in incident CML calls for better patient management


 

Key clinical point: The incidence of chronic myeloid leukemia (CML) has increased globally, but the declining death rate indicates improved treatment options. However, patient management, particularly among elderly patients, needs more attention.

Major finding: The incident cases of CML increased globally by 54.1% from 1990 to 2019. The overall age-standardized death rate declined by 2.55% per year, and disease-adjusted life years (DALY) decreased by 2.69% per year. However, patients aged 70-84 years accounted for higher CML incidence and death cases. Smoking was the biggest risk factor for CML-related DALY (12.2%).

Study details: This study used annual data on the CML burden in 204 countries and regions from 1990 to 2019.

Disclosures: This study was supported by the National Natural Science Foundation of China, Taishan Scholars Program, and Clinical Research Project of Shandong University. The authors declared no conflict of interests.

Source: Hu Y et al. JCO Glob Oncol. 2021 (Sep 30);7:1429-1441. doi: 10.1200/GO.21.00194.

Recommended Reading

CML-CP: Imatinib discontinuation feasible in children with sustained DMR for at least 2 years
MDedge Hematology and Oncology
Patients with CML may continue TKI treatment during COVID-19 pandemic
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: CML October 2021
MDedge Hematology and Oncology
Risk factors associated with COVID-19 mortality in CML patients
MDedge Hematology and Oncology
CML-CP: Elevated creatine kinase levels during first-line TKI treatment associated with improved survival
MDedge Hematology and Oncology
Need for more precise TKI dosing in real-world CML-CP patients
MDedge Hematology and Oncology
Ten-year follow-up continue to support nilotinib in Japanese patients with newly diagnosed CML-CP
MDedge Hematology and Oncology
CML: Better response with first-line new-generation TKI therapy vs. imatinib
MDedge Hematology and Oncology
Allo-HCT outcomes in CML patients previously treated with 2G-TKIs
MDedge Hematology and Oncology
Frontline dasatinib therapy is effective and well tolerated in older patients with CML-CP
MDedge Hematology and Oncology